CR10012A - Formulaciones de proteina de fusión de Inmunoglobulina - Google Patents

Formulaciones de proteina de fusión de Inmunoglobulina

Info

Publication number
CR10012A
CR10012A CR10012A CR10012A CR10012A CR 10012 A CR10012 A CR 10012A CR 10012 A CR10012 A CR 10012A CR 10012 A CR10012 A CR 10012A CR 10012 A CR10012 A CR 10012A
Authority
CR
Costa Rica
Prior art keywords
fusion protein
compositions
immunoglobulin fusion
protein formulations
disaccharide
Prior art date
Application number
CR10012A
Other languages
English (en)
Inventor
Anthony Barry
Thomas Crowley
Daniel Dixon
Jennifer Juneau
Ajay Kumar
Li Li
Nicholas Luksha
Michael Shamashkin
Erin Soley
Nicholas WARNE
Chandra Webb
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR10012A publication Critical patent/CR10012A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a composiciones de proteínas de fusión de Ig, especialmente composiciones que incluyen una proteína de fusión de Ig, un agente de volumen, un disacárido, un tensioactivo, y un amortiguador. En un aspecto, estas composiciones son estables bajo almacenamiento a largo plazo o al menos un ciclo de congelación/descongelación. La invención también proporciona métodos de preparación de las composiciones de proteína de fusión de Ig. En un aspecto, adicional, las composiciones son liofilizadas por un proceso que incluye una etapa de recocido.
CR10012A 2005-11-22 2008-05-22 Formulaciones de proteina de fusión de Inmunoglobulina CR10012A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73927105P 2005-11-22 2005-11-22

Publications (1)

Publication Number Publication Date
CR10012A true CR10012A (es) 2008-07-29

Family

ID=37781927

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10012A CR10012A (es) 2005-11-22 2008-05-22 Formulaciones de proteina de fusión de Inmunoglobulina

Country Status (14)

Country Link
US (2) US20070237758A1 (es)
EP (1) EP1951305A1 (es)
JP (1) JP2009516692A (es)
KR (1) KR20080071192A (es)
CN (1) CN101312744A (es)
AU (1) AU2006318583A1 (es)
BR (1) BRPI0618893A2 (es)
CA (1) CA2630115A1 (es)
CR (1) CR10012A (es)
EC (1) ECSP088459A (es)
NO (1) NO20082133L (es)
RU (1) RU2008118166A (es)
SV (1) SV2009002911A (es)
WO (1) WO2007062040A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7956160B2 (en) * 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
CA2674608A1 (en) * 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
CA2677937A1 (en) * 2007-02-16 2008-08-21 Wyeth Use of sucrose to suppress mannitol-induced protein aggregation
DK2219675T3 (da) * 2007-11-12 2013-12-02 Ares Trading Sa Formuleringer for taci-immunglobulin-fusionsproteiner
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
JP2012530721A (ja) * 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
CN101693016B (zh) * 2009-11-02 2012-07-25 北京美福源生物医药科技有限公司 通用的注射用重组人血清白蛋白融合蛋白制剂配方
AU2010315325B2 (en) 2009-11-03 2014-11-27 Grifols Therapeutics Inc. Composition, method, and kit for alpha-1 proteinase inhibitor
PT2503995T (pt) 2009-11-24 2017-11-23 Grifols Therapeutics Inc Métodos de liofilização, composições e kits
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
CN105435222B (zh) 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
CN104940926B (zh) * 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂
GB201513010D0 (en) * 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020088481A1 (zh) * 2018-10-30 2020-05-07 中国科学院化学研究所 一种制备药物或药物中间体单晶或无定型物的方法
CN111195349B (zh) * 2018-11-16 2023-02-24 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干粉制剂
US20220305094A1 (en) * 2019-01-06 2022-09-29 Endo Global Aesthetics Limited Collagenase formulations and methods of producing the same
MA54861A (fr) 2019-01-31 2021-12-08 Regeneron Pharma Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
CN113125489A (zh) * 2019-12-31 2021-07-16 上海药明生物技术有限公司 生物制剂配方优化和工艺优化的方法和系统
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition
US20240166718A1 (en) * 2021-02-17 2024-05-23 Arecor Limited Aqueous composition of an engineered protein construct comprising an fc domain
WO2022195505A1 (en) * 2021-03-16 2022-09-22 Kashiv Biosciences, Llc Novel formulation of fusion protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
ES2434840T3 (es) * 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP3900664B2 (ja) * 1997-09-26 2007-04-04 株式会社ニコン 顕微鏡
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
DK1820516T3 (da) * 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
CA2371427A1 (en) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
SI1478394T1 (sl) * 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
BRPI0509117A (pt) * 2004-03-04 2007-08-28 Wyeth Corp método de liofilização para melhorar a cristalização de excipientes

Also Published As

Publication number Publication date
SV2009002911A (es) 2009-03-04
US20070237758A1 (en) 2007-10-11
US20110033464A1 (en) 2011-02-10
NO20082133L (no) 2008-06-16
ECSP088459A (es) 2008-06-30
WO2007062040A1 (en) 2007-05-31
EP1951305A1 (en) 2008-08-06
RU2008118166A (ru) 2009-12-27
JP2009516692A (ja) 2009-04-23
BRPI0618893A2 (pt) 2011-09-13
KR20080071192A (ko) 2008-08-01
CA2630115A1 (en) 2007-05-31
CN101312744A (zh) 2008-11-26
AU2006318583A1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
CR10012A (es) Formulaciones de proteina de fusión de Inmunoglobulina
PT2459167E (pt) Formulação subcutânea de anticorpo anti-her2
AR072058A1 (es) Composicion detergente que comprende una variante de la familia 44 de xiloglucanasas
PE20090738A1 (es) Formulaciones de anticuerpos
CY1110157T1 (el) Χιμαιρικα ανασυνδυασμενα αντιγονα του toxoplasma gondii
MX361668B (es) Formulación de anticuerpos.
AR037971A1 (es) Preparacion liofilizada que contiene un anticuerpo contra el receptor egf
ECSP077246A (es) Formulaciones Estabilizadoras
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
AR047949A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial
WO2009073569A3 (en) Protein formulations and methods of making same
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
BR0107436B1 (pt) agente de modificação de reologia, seu processo de preparação, bem como composição com reologia modificada e seu processo de preparação.
CY1114310T1 (el) Νεες ανοσοενισχυτικες συνθεσεις γλυκολιπιδιου
PH12022552132A1 (en) Formulations of human anti-tslp antibodies and methods of using the same
MX2021011530A (es) Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso.
DK1276763T3 (da) Anti-fryseproteiner, deres fremstilling og anvendelse
ATE327783T1 (de) Injizierbare mikrokügelchen für den gewebeaufbau
BRPI0613362A8 (pt) polipeptídeo quimérico, polinucleotídeo, vetor viral, recombinante do sarampo, uso de um vetor viral, anticorpos, vetor, composição imunogênica e método de prevenção e/ou de tratamento de uma infecção
WO2006105441A3 (en) Fiber constructs comprising bioactive materials and process of fiber fabrication
MY140244A (en) Surfactant system
WO2006079722A3 (fr) Compositions pour la lyophilisation de proteines
EA200702243A1 (ru) Температурный режим при щелочной экстракции
AR037304A1 (es) Composiciones liofilizadas de anticuerpos monoclonales

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)